AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: standard

newssourceFORcompanyinformationcontent1releasesmarket

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

Don’t Pay Full Price for Power: WattCycle’s Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15

WattCycle’s June 15-30 sale offers up to 70% off LiFePO4 batteries. Enjoy new arrivals, double points, giveaways & 8% off code: WattCyclePrimeDay.

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX's Pre-IPO and...

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

No Deposit Bonus Casino Real Money 2026 – BetOnline Offered No Deposit Bonuses

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation. 
BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /CNW/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStandard

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers